

Meet The Professors Live: Clinical Investigators Provide Perspectives on Actual Cases of Patients with Ovarian and Endometrial Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following proteins is targeted by raludotatug deruxtecan?
  - a. AKT
  - b. CDH6
  - c. TROP2
  - d. NTRK
2. Which of the following outcomes was observed with olaparib/bevacizumab maintenance among patients with BRCA mutations after 5 years of follow-up in the Phase III PAOLA-1 study?
  - a. No benefit in overall survival (OS)
  - b. A nonsignificant benefit in OS
  - c. A statistically significant benefit in OS
3. Part 2 of the RUBY study demonstrated a progression-free survival advantage with first-line dostarlimab in combination with chemotherapy followed by which of the following maintenance therapies for patients with primary advanced or recurrent endometrial cancer (EC)?
  - a. Selinexor
  - b. Olaparib
  - c. Dostarlimab/niraparib
  - d. Lenvatinib
4. The Phase III KEYNOTE-775 trial demonstrated an OS benefit with the combination of lenvatinib and pembrolizumab versus chemotherapy in which of the following groups of patients with advanced or recurrent EC?
  - a. All-comers
  - b. Those with mismatch repair-proficient (pMMR) disease
  - c. Both all comers and those with pMMR disease
  - d. None of the above
5. On the basis of Phase III trial results, which subgroup of patients is most likely to benefit from receiving selinexor?
  - a. Those with TP53 mutations
  - b. Those with TP53 wild-type disease
  - c. Neither of the above; efficacy was independent of TP53 status